NCT03571087CompletedPhase 3
A Multi Center, Randomized, Double-blind, Parallel, Factorial Design, Therapeutic Phase III Study to Evaluate the Efficacy and Safety of Combination of Rosuvastatin and Ezetimibe in Patients With Primary Hypercholesterolemia
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 3
- Status
- Completed
- Sponsor
- Hanlim Pharm. Co., Ltd.
- Enrollment
- 374
- Primary Endpoint
- Percentage change in LDL-Cholesterol from baseline
Study Overview
Brief Summary
The purpose of this study is to evaluate efficacy and safety of HL140 in patients with primary hypercholesterolemia.
Detailed Description
The purpose of this study is to demonstrate that the efficacy of combination drug of rosuvastatin/ezetimibe is superior to single rosuvastatin drug and to confirm the safety of combination drug of rosuvastatin/ezetimibe
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Triple (Participant, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 19 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Aged over 19 years
- •Signed informed consent form
- •At visit 1 and visit 2, LDL-Cholesterol ≤ 250mg/dL and Triglyceride ≤ 400mg/dL
Exclusion Criteria
- •At visit 1, BMI ≥ 30kg/㎡
- •Has a history of myopathy or rhabdomyolysis cased by statin treatment, hereditary myopathy or family history and hypersensitivity to statin(HMG-CoA reductase inhibitor) and component of ezetimibe
- •Has a Severe renal disorder(Ccr <30mL/min) or nephrotic syndrome
- •Creatine Kinase > 5 x upper limit of normal
- •ALT or AST > 3 x upper limit of normal
- •Has a activity/chronic hepatic disease or HIV-positive
- •Has a endocrine or metabolic diseases known to affect the serum phospholipid or protein
- •Uncontrolled diabetes mellitus(HbA1c ≥9%)
- •Hypothyroidism (TSH > 1.5 x upper limit of normal rate at the screening )
- •Uncontrolled hypertension (SBP ≥180mmHg or DBP ≥110mmHg)
- •Has a acute arteriopathy(history of unstable angina, cardiac infarction, transient ischemic stroke, cerebrovascular disease, coronary artery bypass, coronary intervention within 12 weeks prior to screening)
- •Severe heart failure (NYHA Class III or IV)
- •Has a drug absorption disorder by gastrointestinal surgery or gastrointestinal disorder
- •History of malignant tumor including myelogenous and lymphoma within 5 years (Participation is possible, if the tumor has not recurred for more than 5 years)
- •Subject with genetic deficiency such as galactose intolerance, Lapp lactose deficiency or glucose-galactose malabsorption
- •Female subjects of childbearing potential who disagree with the contraceptive methods(surgical sterilization, intrauterine device or condoms)
- •Pregnant or breast-feeding
- •Patients who have a drug or alcohol abuse or are being treated for psychological disorder
- •Patients who were treated with other investigational drug within 12 weeks prior to screening
- •Other patients who are inappropriate to participate in the study considered by the investigator or other study staffs
Arms & Interventions
HL140 5/10
Experimental
Treatment(W0~W8), Extension(W9~W20): : 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg)
Intervention: HL140 5/10 (Drug)
HL140 10/10
Experimental
Treatment(W0~W8), Extension(W9~W20): : 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg)
Intervention: HL140 10/10 (Drug)
HL140 20/10
Experimental
Treatment(W0~W8), Extension(W9~W20): : 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg)
Intervention: HL140 20/10 (Drug)
Rosuvastatin 5mg → HL140 5/10
Experimental
- Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 5mg
- Extension period(W9~W20): 6Tab./q.d. HL140 5/10(Rosuvastatin5mg/Ezetimibe10mg)
Intervention: Rosuvastatin 5mg → HL140 5/10 (Drug)
Rosuvastatin 10mg → HL140 10/10
Experimental
- Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 10mg
- Extension period(W9~W20): 6Tab./q.d. HL140 10/10(Rosuvastatin10mg/Ezetimibe10mg)
Intervention: Rosuvastatin 10mg → HL140 10/10 (Drug)
Rosuvastatin 20mg → HL140 20/10
Experimental
- Treatment(W0~W8): 6Tab./q.d. Rosuvastatin 20mg
- Extension period(W9~W20): 6Tab./q.d. HL140 20/10(Rosuvastatin20mg/Ezetimibe10mg)
Intervention: Rosuvastatin 20mg → HL140 20/10 (Drug)
Outcomes
Primary Outcomes
Percentage change in LDL-Cholesterol from baseline
Time Frame: Week 8
Percentage change(%) in LDL-Cholesterol from baseline at week 8
Secondary Outcomes
- Percentage change in TG from baseline(Week 4, Week 8)
- Percentage change in TC from baseline(Week 4, Week 8)
- Percentage of change in non-HDL-Cholesterol(Week 4, Week 8)
- The rate of change in hs-CRP(Week 4, Week 8)
- Percentage of patients reached treatment goals according to NCEP ATP III Guideline(Week 4, Week 8)
- Percentage change in LDL-Cholesterol from baseline(Week 4)
- Percentage of change in HDL-Cholesterol(Week 4, Week 8)
- Percentage of change weeks in Apo A-I(Week 4, Week 8)
- Percentage of change in Apo B(Week 4, Week 8)
- Percentage of change in Lipoprotein(a)(Week 4, Week 8)
Investigators
Similar Trials
Completed
Phase 2
Phase II Study of HMPL-004 in Patients With Ulcerative ColitisUlcerative ColitisNCT00659802Hutchison Medipharma Limited224
Completed
Phase 2
Study of DHP1401 in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil(DRAMA)Mild-moderate Alzheimer's DiseaseNCT03055741Daehwa Pharmaceutical Co., Ltd.180
Completed
Phase 3
Efficacy and Safety of HL-040XC in Essential Hypertension and HyperlipidemiaEssential HypertensionHyperlipidemiaNCT01541943HanAll BioPharma Co., Ltd.356
Completed
Phase 3
Safety to Evaluate the Efficacy and Safety of HIP1601 in Patients With Non Erosive Reflux DiseaseNon-erosive Gastroesphageal Reflux DiseaseNCT04325620Hanmi Pharmaceutical Company Limited208
Completed
Phase 2
A Study to Evaluate the Efficacy and Safety of ALH-L1005 in Patients With Chronic PeriodontitisChronic PeriodontitisNCT04503746AngioLab, Inc.117